722 related articles for article (PubMed ID: 24553136)
21. E3 ubiquitin ligase Cbl-b in innate and adaptive immunity.
Liu Q; Zhou H; Langdon WY; Zhang J
Cell Cycle; 2014; 13(12):1875-84. PubMed ID: 24875217
[TBL] [Abstract][Full Text] [Related]
22. Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells.
Loeser S; Loser K; Bijker MS; Rangachari M; van der Burg SH; Wada T; Beissert S; Melief CJ; Penninger JM
J Exp Med; 2007 Apr; 204(4):879-91. PubMed ID: 17403934
[TBL] [Abstract][Full Text] [Related]
23. CD2-associated protein (CD2AP) enhances casitas B lineage lymphoma-3/c (Cbl-3/c)-mediated Ret isoform-specific ubiquitination and degradation via its amino-terminal Src homology 3 domains.
Calco GN; Stephens OR; Donahue LM; Tsui CC; Pierchala BA
J Biol Chem; 2014 Mar; 289(11):7307-19. PubMed ID: 24425877
[TBL] [Abstract][Full Text] [Related]
24. E3 ubiquitin ligase CBLB regulates innate immune responses and bacterial dissemination during nontuberculous mycobacteria infection.
Sharma J; Mudalagiriyappa S; Abdelaal HFM; Kelly TC; Choi W; Ponnuraj N; Vieson MD; Talaat AM; Nanjappa SG
J Leukoc Biol; 2024 May; 115(6):1118-1130. PubMed ID: 38271280
[TBL] [Abstract][Full Text] [Related]
25. T cell activation threshold regulated by E3 ubiquitin ligase Cbl-b determines fate of inducible regulatory T cells.
Qiao G; Zhao Y; Li Z; Tang PQ; Langdon WY; Yang T; Zhang J
J Immunol; 2013 Jul; 191(2):632-9. PubMed ID: 23749633
[TBL] [Abstract][Full Text] [Related]
26. Pro-prion, as a membrane adaptor protein for E3 ligase c-Cbl, facilitates the ubiquitination of IGF-1R, promoting melanoma metastasis.
Li H; Zhang J; Ke JR; Yu Z; Shi R; Gao SS; Li JF; Gao ZX; Ke CS; Han HX; Xu J; Leng Q; Wu GR; Li Y; Tao L; Zhang X; Sy MS; Li C
Cell Rep; 2022 Dec; 41(12):111834. PubMed ID: 36543142
[TBL] [Abstract][Full Text] [Related]
27. Cbl-b Is Upregulated and Plays a Negative Role in Activated Human NK Cells.
Lu T; Chen L; Mansour AG; Yu MJ; Brooks N; Teng KY; Li Z; Zhang J; Barr T; Yu J; Caligiuri MA
J Immunol; 2021 Feb; 206(4):677-685. PubMed ID: 33419766
[TBL] [Abstract][Full Text] [Related]
28. E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis.
Sévère N; Dieudonné FX; Marie PJ
Cell Death Dis; 2013 Jan; 4(1):e463. PubMed ID: 23328670
[TBL] [Abstract][Full Text] [Related]
29. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
[TBL] [Abstract][Full Text] [Related]
30. Casitas b cell lymphoma‑B (Cbl-b): A new therapeutic avenue for small-molecule immunotherapy.
Hu X; Li E; Zhou Y; You Q; Jiang Z
Bioorg Med Chem; 2024 Mar; 102():117677. PubMed ID: 38457911
[TBL] [Abstract][Full Text] [Related]
31. Axl signaling induces development of natural killer cells in vitro and in vivo.
Kim EM; Lee EH; Lee HY; Choi HR; Ji KY; Kim SM; Kim KD; Kang HS
Protoplasma; 2017 Mar; 254(2):1091-1101. PubMed ID: 27549806
[TBL] [Abstract][Full Text] [Related]
32. E3 Ubiquitin Ligase Cbl-b Prevents Tumor Metastasis by Maintaining the Epithelial Phenotype in Multiple Drug-Resistant Gastric and Breast Cancer Cells.
Xu L; Zhang Y; Qu X; Che X; Guo T; Cai Y; Li A; Li D; Li C; Wen T; Fan Y; Hou K; Ma Y; Hu X; Liu Y
Neoplasia; 2017 Apr; 19(4):374-382. PubMed ID: 28334634
[TBL] [Abstract][Full Text] [Related]
33. Differential control of CD28-regulated in vivo immunity by the E3 ligase Cbl-b.
Krawczyk CM; Jones RG; Atfield A; Bachmaier K; Arya S; Odermatt B; Ohashi PS; Penninger JM
J Immunol; 2005 Feb; 174(3):1472-8. PubMed ID: 15661906
[TBL] [Abstract][Full Text] [Related]
34. The Ubiquitin Ligases c-Cbl and Cbl-b Negatively Regulate Platelet-derived Growth Factor (PDGF) BB-induced Chemotaxis by Affecting PDGF Receptor β (PDGFRβ) Internalization and Signaling.
Rorsman C; Tsioumpekou M; Heldin CH; Lennartsson J
J Biol Chem; 2016 May; 291(22):11608-18. PubMed ID: 27048651
[TBL] [Abstract][Full Text] [Related]
35. Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities.
Lew ED; Oh J; Burrola PG; Lax I; Zagórska A; Través PG; Schlessinger J; Lemke G
Elife; 2014 Sep; 3():. PubMed ID: 25265470
[TBL] [Abstract][Full Text] [Related]
36. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
[TBL] [Abstract][Full Text] [Related]
37. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
[TBL] [Abstract][Full Text] [Related]
38. Rapidly fatal myeloproliferative disorders in mice with deletion of Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cells.
Naramura M; Nandwani N; Gu H; Band V; Band H
Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16274-9. PubMed ID: 20805496
[TBL] [Abstract][Full Text] [Related]
39. Tyro3, Axl, and Mertk receptors differentially participate in platelet activation and thrombus formation.
Zhou J; Yang A; Wang Y; Chen F; Zhao Z; Davra V; Suzuki-Inoue K; Ozaki Y; Birge RB; Lu Q; Wu Y
Cell Commun Signal; 2018 Dec; 16(1):98. PubMed ID: 30541554
[TBL] [Abstract][Full Text] [Related]
40. Ubiquitin ligase Cbl-b and inhibitory Cblin peptides.
Nikawa T; Ishidoh K
Biochim Biophys Acta Proteins Proteom; 2020 Nov; 1868(11):140495. PubMed ID: 32663526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
